RET and medullary thyroid gland carcinoma: Subsequently, these gatekeeper mutations were shown to emerge in patients with RET-altered MTC or NSCLC after treatment with either vandetanib or cabozantinib (Dagogo-Jack et al. 2018, Subbiah et al. 2018a,b, Wirth et al. 2019) (Supplementary Table (see the section on Supplementary materials given at the end of the article)).